1. Pink Sheet
  2. >>Pathways & Standards
  3. >>User Fees

PDUFA VII: US FDA Wants Dedicated RMAT Program Funding

 
• By Derrick Gingery

Cell and gene therapy product activities also have increased CBER’s workload significantly and strained staff, the agency tells industry representatives.

Gene Therapy for Cancer Treatment Concept Cancer therapy with T-cell and pipette and vials - Image
The increased cell and gene therapy workload forced CBER staff to limit sponsor interactions and convert live meetings to "written responses only" status. • Source: Shutterstock

The Regenerative Medicine Advanced Therapy (RMAT) designation could gain dedicated funding as part of cell and gene therapy program enhancements in the US Food and Drug Administration’s prescription drug user fee reauthorization.

Minutes of a 29 September virtual PDUFA VII CBER subgroup negotiating session indicate the agency proposed dedicated resources for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

US FDA’s Prescription And Generic Drug User Fee Collections May Miss FY 2025 Targets

 
• By Sue Sutter

Both programs were expected to slightly under-collect fees, similar to FY 2024, but an assessment determined the capacity planning adjustment was accurately forecasting the necessary revenue.

October US FDA User Fee Goals: Few Novel Agents, But Many New Indications As Shutdown Looms

 
• By Bridget Silverman

October is unusually low on user fee goals for novel agents, but more than 20 applications for new indications and formulations will keep FDA staff busy, especially in oncology and ophthalmology.

Shutdown Approaches: US FDA Would Retain Most Of Recently Trimmed Staff

 
• By Derrick Gingery

FDA shutdown plans indicate about 86% of staff would be retained, a rate that is higher than previous plans, but reserve funding would not last more than a few months.

More NME Reviews, Reduced Costs Combine To Lower US FDA Voucher Fee

 
• By Derrick Gingery

The FDA said new molecular entity application reviews increased and cost less in fiscal year 2024, a potentially encouraging sign for industry.

More from Pathways & Standards

October US FDA User Fee Goals: Few Novel Agents, But Many New Indications As Shutdown Looms

 
• By Bridget Silverman

October is unusually low on user fee goals for novel agents, but more than 20 applications for new indications and formulations will keep FDA staff busy, especially in oncology and ophthalmology.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US FDA’s Tidmarsh Takes On Surrogate Endpoints, Maybe Old Business Partner, On LinkedIn

 
• By Sarah Karlin-Smith

CDER Director George Tidmarsh said in a now deleted social media post that his center will evaluate surrogate endpoints. Tidmarsh mentioned "notable failures," including a lupus drug, where he has past business connections to the sponsor's board chair.